Fig. 3

Comparisons of absolute values in the ratio of neoepitope collagen synthesis to degradation markers in healthy controls and participants with stable and progressive IPF, measured at baseline, 1, 3 and 6 months for: collagen-type 1 (P1NP:C1M), −type 3 (PRO-C3:C3M) and -type 6 (PRO-C6:C6M). Plots represent mean and 95% CI (error bars) adjusted for age, sex, site and smoking status. Disease progression was defined as all-cause mortality or ≧10% decline in forced vital capacity at 12 months. The number of evaluable samples available for analysis at each time point are provided in the graph. P values are provided where significant (p < 0.05) differences were observed between stable and progressive disease at a particular time point. Triangles represent which groups were compared at each time point on the graph, based on colour